- Home
- PYXS vs AVIR Comparison
PYXS vs AVIR Comparison
Compare PYXS & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PYXS | AVIR |
|---|---|---|
| Founded | 2018 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.6M | 318.0M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PYXS | AVIR |
|---|---|---|
| Price | $1.56 | $6.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | $6.75 | ★ $8.00 |
| AVG Volume (30 Days) | 296.1K | ★ 553.4K |
| Earning Date | 01-01-0001 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.65 | 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | $16,146,000.00 | ★ $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.84 | $2.46 |
| 52 Week High | $5.55 | $6.45 |
Technical Indicators
Market Signals| Indicator | PYXS | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 52.16 | 77.44 |
| Support Level | $1.27 | $3.33 |
| Resistance Level | $1.69 | N/A |
| Average True Range (ATR) | 0.09 | 0.30 |
| MACD | 0.03 | 0.14 |
| Stochastic Oscillator | 78.57 | 80.00 |
Price Performance
Historical ComparisonAbout PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).